hit counter

High Cytokines Predicted Weaker Placebo Response in Cancer Symptom Trial

MHD featured image for cytokine biomarkers and placebo response in cancer symptom trials.

A 2026 exploratory analysis of the ABCD cancer dyspnea trial found that higher baseline cytokines predicted less placebo symptom improvement than lower baseline cytokines across 33 of 40 cytokine-symptom combinations at day 7 and 29 of 40 at day 14.1 The signal is not ready for clinical prediction, but it sharpens a trial-design problem: patients …

Read more

Early Psychosis Vocational Recovery: 53.3% NEET in SEEearly Trial

MHD featured image for early psychosis, supported employment and education, and NEET status.

A 2026 SEEearly baseline report found that 53.3% of 184 young people with early schizophrenia-spectrum psychosis were not in employment, education, or training at study entry, even though 97.8% had at least a lower- or upper-secondary school-leaving qualification.1 Psychosis had already interrupted the bridge from school into training, college, or competitive work. Research Highlights NEET …

Read more

ALS Entropy Analysis Finds 5-Month Signal Hidden by ALSFRS Scores

MHD featured image for ALS trial endpoints, Shannon entropy, and ALSFRS domain trajectories.

A 2026 PRO-ACT analysis of amyotrophic lateral sclerosis (ALS) trial data found a signal that ordinary ALSFRS total-score slopes cannot even express: Shannon entropy trajectories diverged between pooled active and placebo arms, including a 5-month delay in peak Fine Motor distributional spread for active-arm patients.1 Research Highlights Entropy found an endpoint-level signal: Rodriguez analyzed 7,512 …

Read more

Risperidone in Dementia Raised Stroke-Related Events 4.11x by Week 4

MHD featured image for risperidone adverse events in dementia.

A 2026 individual participant data meta-analysis of 1,721 dementia trial participants linked risperidone to cerebrovascular adverse events, HR 4.11 (95% CI 1.77 to 9.51), and major cardiovascular adverse events, HR 2.00 (95% CI 1.23 to 3.26).1 The timing signal is the practical warning: median first cerebrovascular event appeared at 4.3 weeks, and median first major …

Read more

sCD27 Biomarker Flags Autoimmune Disease in Severe Psychiatric Disorders

MHD featured image for sCD27, autoimmune disease, severe psychiatric disorders, and neuroinflammation biomarker triage.

A 2026 immunopsychiatry cohort study found that soluble CD27 (sCD27), a marker of T-cell activation, was positive in cerebrospinal fluid in 23% of severe psychiatric patients selected for suspected immune involvement and in 88% of multiple sclerosis patients used as a positive-control group. In the psychiatric cohort, combined cerebrospinal fluid or blood sCD27 positivity was …

Read more

Parkinson’s Speech Pauses Track Sentence Complexity and MoCA Scores

MHD featured image for Parkinson's speech pauses, sentence complexity, MoCA scores, and dysarthria.

A 2026 connected-speech study found that people with Parkinson’s disease produced more silent pauses than older controls while reading aloud: 2.185 vs. 1.595 mean pauses, while long sentences produced 2.676 pauses vs. 1.033 in short sentences.1 Within the Parkinson’s group, MoCA scores correlated with total pause count (rs = −0.502, p = 0.005). Research Highlights …

Read more